– USA, CA – Bolt Biotherapeutics (Nasdaq: BOLT) today announced the appointment of Dr. Nicole Onetto, (M.D.) to its Board of Directors, effective Dec. 14, 2021.
“Nicole’s extensive experience in clinical development and translational research makes her an excellent addition to the Bolt Biotherapeutics Board of Directors. Nicole’s work overseeing oncology drug development programs at cancer research institutions, biotechnology and pharmaceutical companies will be invaluable to Bolt as we advance our innovative immuno-oncology clinical programs and expand our pipeline,” said CEO, Dr. Randall Schatzman.
Concurrently, Dr. Ashish Khanna will be stepping down from the board of directors.
About Dr. Nicole Onetto
Dr. Onetto brings 30 years of experience primarily focused on the field of oncology at biotechnology, pharmaceutical, and academic research institutions. She currently serves as an independent consultant in oncology, drug development, and translational research, and on the Board of Directors at Viracta Therapeutics and Basilea Pharmaceutica. She previously served on the Board of Directors for NBE Therapeutics, Sierra Oncology, and ImmunoGen. Before that, Dr. Onetto held leadership roles at the Ontario Institute of Cancer Research, where she was Deputy Director and CSO, and at ZymoGenetics (Bristol Myers Squibb) and OSI Pharmaceuticals (Astellas), where she held the position of CMO. Her career also includes senior management positions at Bristol Myers Squibb, Gilead Sciences, and Immunex Corporation (Amgen). Dr. Onetto earned her bachelor’s degree from the University of Paris, a master’s degree in Pharmacology from the University of Montréal, and her medical degree and a Hematology-Oncology Certificate from the University of Paris.
“Developing safe and effective approaches to stimulating the innate and adaptive immune system is one of the next great frontiers for the treatment of patients with cancers at all stages of development. I look forward to sharing my experience and contributing to the groundbreaking work at Bolt Biotherapeutics in developing new immuno-oncology therapeutics that leverage the Boltbody™ ISAC platform,” said Dr. Onetto.
About Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems Bolt’s proprietary Boltbody Immune-stimulating Antibody Conjugate approach uses immunostimulants to engage and activate myeloid cells that directly kill tumor cells. This leads to the conversion of immunologically “cold” tumors to “hot” tumors. Bolt’s lead candidate, BDC-1001, is a Boltbody ISAC comprised of a HER2-targeting biosimilar of trastuzumab conjugated to one of Bolt’s proprietary TLR7/8 agonists for the treatment of patients with HER2-expressing solid tumors. Bolt is also advancing additional Boltbody ISAC product candidates targeting CEA and PD-L1.
For more information: https://www.boltbio.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.